arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Eloxx Pharmaceuticals, Inc.

ELOX
$15.80 ▼ -1.29 (-7.58%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
69 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Eloxx Pharmaceuticals, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $107.3M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -7.6%
FCF / Share $-0.71
Trailing P/E
Price / Book 1.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.79M
↑ +12.6%
Net Income Profit after all expenses
$-3.75M
↓ -119.7%
FCF / Share Free cash flow per share
$-0.71
↑ +86.0%
Long-Term Debt Long-term obligations
$1.00M
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
98
Financial Health
63
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 27 years · 69 quarters